

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Fisher & Paykel Healthcare provides first half guidance for FY26; director Pip Greenwood to retire

Auckland, New Zealand, 21 August 2025 – Fisher & Paykel Healthcare Corporation Limited today provided guidance for the first half of the 2026 financial year, which ends 30 September 2025.

At 31 July exchange rates*, guidance assumptions for the first half of the 2026 financial year include a continuation of the current trading environment and result in revenue of approximately \$1.075 billion and net profit after tax of approximately \$200 million. This would equate to approximately 13% growth in reported operating revenue and approximately 31% growth in reported net profit after tax, compared to the first half of the 2025 financial year.

“We had a very strong first half last year across both Homecare and Hospital product groups, with 17% revenue growth in constant currency. Against that backdrop, an ongoing change in clinical practice to our Hospital therapies continues to contribute to our outlook for strong growth for the first half of this year,” said Managing Director and CEO Lewis Gradon.

Outlook for the 2026 financial year

At 31 July exchange rates*, the company’s outlook for the full year remains unchanged, with operating revenue in the range of approximately \$2.15 billion to \$2.25 billion and net profit after tax in the range of approximately \$390 million to \$440 million.

This outlook now includes an estimated 75-basis point impact of US tariffs on hospital products sourced from New Zealand. It also assumes current global tariff rates, policies and applications for the duration of this financial year.

Board director Pip Greenwood to retire

Director Pip Greenwood has announced her intention to retire from the board of Fisher & Paykel Healthcare with effect from 1 September 2025. Ms Greenwood has served as an independent director of Fisher & Paykel Healthcare since June 2017 and was recently appointed to the Australian board of Westpac Banking Corporation. She also chairs the boards of both The a2 Milk Company and Westpac New Zealand.

“With my recent appointment to the Westpac Australia board and my workload across the other three boards, I have reassessed my portfolio and have made the difficult decision to retire from the board of Fisher & Paykel Healthcare after eight years. It has been incredible what Fisher & Paykel Healthcare has achieved over the last decade, and I feel proud to have been involved with this company at such a pivotal time in its growth.”

Board Chair Neville Mitchell said, “We acknowledge Pip’s significant contribution to our company. She has provided wise counsel and has been a valued board colleague. With Pip stepping away, we will shortly commence the process of appointing another director.”

Annual Shareholders’ Meeting 2025

Fisher & Paykel Healthcare has provided speeches and slide presentations for the 2025 Annual Shareholders’ Meeting to the NZX and ASX today. The meeting will be held today at 2:00pm NZST, 12:00pm AEST (10:00pm US EDT) and will be broadcast online.

To participate go to: <http://www.virtualmeeting.co.nz/fph25>.

* 31 July 2025 exchange rates of NZD:USD 0.59, NZD:EUR 0.52, NZD:MXN 11.15

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com

Contacts:

Media

Karen Knott
GM Corporate Communications
karen.knott@fphcare.co.nz
+64 21 713 911

Investors

Daniel Adolph
Head of Investor Relations
daniel.adolph@fphcare.co.nz
+64 22 511 4050

Authorised by Fisher & Paykel Healthcare Corporation Limited's Board of Directors.